Hikma's Roxicet ANDA089351 Receives Abbreviated Approval from FDA
Hikma's Abbreviated New Drug Application (ANDA) for Roxicet has received approval from the FDA.
Asset / Drug
Drug and asset intelligence for Roxicet with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.